文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性的基因治疗:原理、临床试验与未来方向

Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions.
PubMed 文献 · Br J Ophthalmol · 2020-04-08

新生血管性年龄相关性黄斑变性(nAMD)需反复玻璃体腔注射抗VEGF药物,给医疗系统和患者带来巨大负担。基因治疗通过持续递送抗血管生成蛋白有望解决这一问题,早期临床试验结果令人鼓舞,但最佳治疗靶点、给药途径和安全性仍存争议。本文综述了nAMD基因治疗的现状并简要讨论未来前景。

要点

  • 抗VEGF治疗需反复甚至终身玻璃体腔注射,相关并发症、高药费、频繁就诊和重复影像检查造成巨大负担。
  • 基因治疗可持续递送抗血管生成蛋白,早期临床试验结果令人鼓舞,更多试验正在进行或即将开展。
  • 最佳治疗靶点、给药途径和潜在安全性问题仍存在显著争议。

核心结论

  • 基因治疗通过持续递送抗血管生成蛋白有望解决nAMD反复注射带来的负担,早期临床试验结果令人鼓舞但争议仍存。

研究设计与样本

  • 本文为综述,旨在更新nAMD基因治疗的当前状态并简要讨论未来前景。

主要发现

  • 多项nAMD基因治疗早期临床试验结果令人鼓舞,许多试验正在进行或预期开展。

临床怎么用

  • 基因治疗有望通过持续递送抗血管生成蛋白减少反复玻璃体腔注射及其相关负担。

局限性

  • 最佳治疗靶点、给药途径和潜在安全性问题仍存在显著争议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developed world. Antivascular endothelial growth factor therapy has transformed the management and outcome of neovascular AMD (nAMD), although the need for repeated intravitreal injections-even lifelong-and the related complications, high drug costs, frequent clinic visits and repeated imaging have resulted in an enormous burden both to healthcare systems and patients. The application of gene therapy approaches for sustained delivery of a range of antiangiogenic proteins has the promise of helping to address these aforementioned challenges. A number of early phase clinical trials of gene therapy in nAMD have provided encouraging results, with many more ongoing or anticipated. There remain significant areas of controversy, including regarding the optimal treatment targets, routes of administration and potential safety concerns. In this review we aim to provide an update of the current status of gene therapy for nAMD and briefly discuss future prospects.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Guimaraes TAC, Georgiou M, Bainbridge JWB, et al. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. Br J Ophthalmol. 2020. PMID: 32269060. doi:10.1136/bjophthalmol-2020-316195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。